The US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.043 USD | +38.71% | +43.33% | -93.86% |
08/05 | Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation | CI |
11/04 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
1st Jan change | Capi. | |
---|---|---|
-93.86% | 434K | |
+37.74% | 723B | |
+34.77% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.10% | 244B | |
+10.06% | 208B | |
-4.13% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation